Physician profile
Mohsin M Cheema
NPI 1699747063
$5,809.33
in general payments reported to CMS, 2019-2025
24 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $520 · 2021: $438 · 2022: $566 · 2023: $2,410 · 2024: $681 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,821 · Food and Beverage: $1,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,820.72 |
| Food and Beverage | $1,756.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $2,140.17 | 2023-2025 | Iolmaster 700, Veracity Surgical, Visumax |
| Abbvie INC. | $672.83 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Alcon Vision LLC | $564.21 | 2019-2025 | Tryptyr, Rocklatan, Clareon |
| Allergan, INC. | $429.17 | 2019-2022 | |
| Rxsight INC | $314.52 | 2024 | Rxsight Injector Handpiece, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Aerie Pharmaceuticals, INC. | $281.90 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $247.61 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $247.26 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Novartis Pharmaceuticals Corporation | $189.43 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $152.75 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $144.27 | 2020-2024 | |
| Tarsus Pharmaceuticals, INC. | $74.40 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $49.09 | 2019-2021 | |
| Shire North American Group INC | $47.96 | 2019 | |
| Ocular Therapeutix, INC. | $40.25 | 2021-2023 | Dextenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Oyster Point Pharma, INC. | $34.01 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $31.80 | 2025 | |
| Lombart Brothers, INC. | $23.83 | 2025 | Opd-III |
| Sight Sciences, INC. | $22.40 | 2022 | |
| Biotissue Holdings INC. | $20.06 | 2025 | |
| Mallinckrodt Hospital Products INC. | $17.76 | 2024 | Acthar |
| Thea Pharma INC. | $13.76 | 2024 | Iyuzeh |
| Lensar, INC. | $11.09 | 2024 | Lensar Laser System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsin Cheema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.